Literature DB >> 9858792

Influence of alpha-thalassemia on cholelithiasis in SS patients with elevated Hb F.

M Z Haider1, S Ashebu, P Aduh, A D Adekile.   

Abstract

Chronic hemolysis, with consequent hyperbilirubinemia, predisposes SS patients to pigment gallstones. The other factors which influence the development of stones in these patients have not been identified. We have carried out a combined prospective and retrospective study of SS patients in Kuwait and specifically investigated the influence of coexistent alpha-thal trait on the prevalence of gallstones. A total of 45 patients (30 males, 15 females) with ages ranging from 1 to 16 years (mean 7.2 +/- 3.1) were studied. Most were either homozygotes for the Saudi Arabia/India haplotype (86.7%) or compound heterozygotes for this and the Benin haplotype (11.1%). They were screened for gallstones with ultrasonography. alpha-Globin genotypes were determined using a combination of PCR and allele-specific oligonucleotide hybridization techniques to identify the common alpha-thalassemia alleles in this population. Gallstones were detected in 7 (15.6%) patients (4 males, 3 females), whose mean age (10.5 +/- 5.5 years) was significantly higher than that (6.8 +/- 3.2 years) of those without stones (p < 0.01). The mean total Hb of the former (8.4 +/- 0.8 g/dl) was also significantly (p < 0.05) lower than in the latter (9.5 +/- 1.3 g/dl), while the difference in mean Hb F levels was not significant. None of the 4 alpha-thal homozygotes had gallstones while 2 of 13 heterozygotes and 5 of the 23 patients without coexistent alpha-thal had. The differences in these proportions are statistically significant (chi2 = 20.4, p < 0. 001). It therefore appears that coexistent alpha-thal decreases the chance of developing gallstones in Arab SS patients. This may be related to less hemolysis in such patients as shown by their higher mean Hb level.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9858792     DOI: 10.1159/000040890

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  8 in total

1.  Alpha thalassemia, but not βS-globin haplotypes, influence sickle cell anemia clinical outcome in a large, single-center Brazilian cohort.

Authors:  Betânia Lucena Domingues Hatzlhofer; Diego Antonio Pereira-Martins; Igor de Farias Domingos; Gabriela da Silva Arcanjo; Isabel Weinhäuser; Diego Arruda Falcão; Isabela Cristina Cordeiro Farias; Jéssica Vitória Gadelha de Freitas Batista; Luana Priscilla Laranjeira Prado; Jéssica Maria Florencio Oliveira; Thais Helena Chaves Batista; Marcondes José de Vasconcelos Costa Sobreira; Rodrigo Marcionilo de Santana; Amanda Bezerra de Sá Araújo; Manuela Albuquerque de Melo; Bruna Vasconcelos de Ancântara; Juan Luiz Coelho-Silva; Ana Beatriz Lucas de Moura Rafael; Danízia Menezes de Lima Silva; Flávia Peixoto Albuquerque; Magnun Nueldo Nunes Santos; Ana Cláudia Dos Anjos; Fernando Ferreira Costa; Aderson da Silva Araújo; Antonio Roberto Lucena-Araújo; Marcos André Cavalcanti Bezerra
Journal:  Ann Hematol       Date:  2021-02-13       Impact factor: 3.673

2.  Influence of alpha thalassemia on clinical and laboratory parameters among nigerian children with sickle cell anemia.

Authors:  Oladele S Olatunya; Dulcineia M Albuquerque; Adekunle Adekile; Fernando F Costa
Journal:  J Clin Lab Anal       Date:  2018-08-20       Impact factor: 2.352

3.  Influence of UGT1A1 promoter polymorphism, α-thalassemia and βs haplotype in bilirubin levels and cholelithiasis in a large sickle cell anemia cohort.

Authors:  Jéssica V G F Batista; Gabriela S Arcanjo; Thais H C Batista; Marcondes J Sobreira; Rodrigo M Santana; Igor F Domingos; Betânia L Hatzlhofer; Diego A Falcão; Diego A Pereira-Martins; Jéssica M Oliveira; Amanda S Araujo; Luana P M Laranjeira; Fernanda S Medeiros; Flávia P Albuquerque; Dulcinéia M Albuquerque; Magnun N Santos; Manuela F Hazin; Ana C Dos Anjos; Fernando F Costa; Aderson S Araujo; Antonio R Lucena-Araujo; Marcos A Bezerra
Journal:  Ann Hematol       Date:  2021-02-01       Impact factor: 3.673

Review 4.  Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management.

Authors:  Samir K Ballas; Muge R Kesen; Morton F Goldberg; Gerard A Lutty; Carlton Dampier; Ifeyinwa Osunkwo; Winfred C Wang; Carolyn Hoppe; Ward Hagar; Deepika S Darbari; Punam Malik
Journal:  ScientificWorldJournal       Date:  2012-08-01

5.  Early modification of sickle cell disease clinical course by UDP-glucuronosyltransferase 1A1 gene promoter polymorphism.

Authors:  Rute Martins; Anabela Morais; Alexandra Dias; Isabel Soares; Cristiana Rolão; J L Ducla-Soares; Lígia Braga; Teresa Seixas; Baltazar Nunes; Gabriel Olim; Luísa Romão; João Lavinha; Paula Faustino
Journal:  J Hum Genet       Date:  2008-04-05       Impact factor: 3.172

6.  A genome-wide association study of total bilirubin and cholelithiasis risk in sickle cell anemia.

Authors:  Jacqueline N Milton; Paola Sebastiani; Nadia Solovieff; Stephen W Hartley; Pallav Bhatnagar; Dan E Arking; Daniel A Dworkis; James F Casella; Emily Barron-Casella; Christopher J Bean; W Craig Hooper; Michael R DeBaun; Melanie E Garrett; Karen Soldano; Marilyn J Telen; Allison Ashley-Koch; Mark T Gladwin; Clinton T Baldwin; Martin H Steinberg; Elizabeth S Klings
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

7.  Serum Total Bilirubin, not Cholelithiasis, is Influenced by UGT1A1 Polymorphism, Alpha Thalassemia and β(s) Haplotype: First Report on Comparison between Arab-Indian and African β(s) Genes.

Authors:  Said Y Alkindi; Anil Pathare; Shoaib Al Zadjali; Vinodhkumar Panjwani; Fauzia Wasim; Hammad Khan; Pradeep Chopra; Rajagopal Krishnamoorthy; Salam Alkindi
Journal:  Mediterr J Hematol Infect Dis       Date:  2015-11-01       Impact factor: 2.576

8.  UGT1A1 promoter polymorphism associated with serum bilirubin level in Saudi patients with sickle cell disease.

Authors:  Zainab Hamad; Abdullah Aljedai; Rabih Halwani; Abdulrahman AlSultan
Journal:  Ann Saudi Med       Date:  2013 Jul-Aug       Impact factor: 1.526

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.